- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06671457
Model-Driven Individualized Transcranial Direct Current Stimulation for the Treatment of Insomnia Disorders
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Zhen Wang, PhD,MD
- Phone Number: +86 34773516
- Email: wangzhen@smhc.org.cn
Study Contact Backup
- Name: Zhen Wang, PhD,MD
- Phone Number: +86 64387250
- Email: wangzhen@smhc.org.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Recruiting
- Shanghai Mental Health Center
-
Contact:
- Zhen Wang
- Phone Number: +86 64387250
- Email: wangzhen@smhc.org.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 18 and 65 years;
- Meets the diagnostic criteria for insomnia disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
- Has not taken psychiatric medications in the 8 weeks prior to enrollment or has been on stable psychiatric medication for 8 weeks (excluding benzodiazepines);
- Insomnia severity as indicated by an ISI score > 10;
- Minimum education level of junior high school or above.
Exclusion Criteria:
- Past or current diagnosis of disorders other than insomnia disorder, anxiety disorder, or depressive disorder according to DSM-5;
- Currently using benzodiazepines as sleep aids;
- Moderate to severe anxiety or depression (HAMD-17 score > 16 or HAMA score > 24);
- Patients with obstructive sleep apnea syndrome;
- Previous treatment with ECT, rTMS, tES, or cognitive behavioral therapy for insomnia disorder;
- Severe physical illnesses or any condition that may induce seizures or intracranial hypertension, including cardiovascular or respiratory diseases;
- History of neurological disorders (e.g., epilepsy, cerebrovascular accidents) or history of brain injury or brain surgery;
- Presence of implantable medical devices such as intracranial stents, cardiac pacemakers, coronary stents, or cochlear implants;
- Severe negative thoughts or high suicide risk;
- Pregnant or planning to conceive in the near future.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Active Group
To optimize stimulation parameters, electromagnetic modeling and parameter space scanning of the participant's brain are conducted.
The specific method includes performing MRI scans before stimulation.
MRI structural data is then used to create individualized models of the participant's brain and simulate the electromagnetic fields within biological tissues.
High-density EEG is collected during the participant's sleep state, using a 256-channel stimulation-recording device (MagStim EGI, GTEN 200) to record EEG changes induced by stimulation across multiple brain regions.
The type of electrical stimulation is cathodal direct current stimulation, targeting brain regions with an intensity equivalent to the traditional 2mA single-channel current, with each electrode not exceeding 200μA.
Target brain regions for stimulation include the dorsolateral prefrontal cortex (DLPFC), orbitofrontal cortex (OPFC), medial prefrontal cortex (mPFC), and posterior cingulate cortex (PCC).
Changes in brain
|
The intervention uses transcranial direct current stimulation (tDCS). The targeted brain regions are identified by conducting simultaneous fMRI-EEG data collection and sleep staging, comparing fMRI data between wakefulness and sleep states. Brain regions that show differences are calculated as potential targets for electrical stimulation. If no differentiated regions are found in a participant, specific areas are chosen based on individualized modeling results from previous experiments, targeting areas such as the dorsolateral prefrontal cortex (DLPFC), orbitofrontal cortex (OPFC), medial prefrontal cortex (mPFC), and posterior cingulate cortex (PCC). Two regions are selected within each brain area for parameter scanning (with each stimulation lasting 10 seconds and EEG data recorded 10 seconds before and after stimulation). In our prior studies, we observed a decrease in EEG microstate complexity during sleep, with electrical stimulation influencing this complexity reduction to some |
|
Sham Comparator: Sham Group
In the sham stimulation group, the placement of the tDCS electrodes is identical to that of the active stimulation group.
After the stimulation begins, the current gradually increases over 15 seconds.
However, upon reaching the therapeutic current level, it immediately begins to decrease, lowering to 0 mA within 15 seconds and remaining at 0 mA throughout the rest of the session.
During the last 15 seconds of the stimulation, there is another gradual decrease in current to 0 mA.
This approach creates a similar subjective sensation to the real stimulation, making it difficult for participants to discern which type of electrical stimulation they are receiving.
|
In the sham stimulation group, the placement of the tDCS electrodes is identical to that of the active stimulation group.
After the stimulation begins, the current gradually increases over 15 seconds.
However, upon reaching the therapeutic current level, it immediately begins to decrease, lowering to 0 mA within 15 seconds and remaining at 0 mA throughout the rest of the session.
During the last 15 seconds of the stimulation, there is another gradual decrease in current to 0 mA.
This approach creates a similar subjective sensation to the real stimulation, making it difficult for participants to discern which type of electrical stimulation they are receiving.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insomnia Severity Index change
Time Frame: The study endpoint is set at 2 weeks after the end of treatment
|
The change of the Insomnia Severity Index (ISI) score.The scale consists of 7 items, scored on a 5-point Likert scale ranging from 0 to 4 for each item, with a total score ranging from 0 to 28.
Higher scores indicate more severe insomnia.
|
The study endpoint is set at 2 weeks after the end of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
response/remission rate
Time Frame: After tDCS intervention, 2 weeks post-intervention, and 4 weeks post-intervention
|
Treatment effectiveness is defined as a reduction of more than 7 points in the Insomnia Severity Index (ISI) score post-treatment.
Clinical remission is defined as a total ISI score of less than 8 points.
|
After tDCS intervention, 2 weeks post-intervention, and 4 weeks post-intervention
|
|
Sleep onset latency, sleep efficiency, and nighttime sleep duration (as defined by the sleep diary).
Time Frame: After tDCS intervention and 2 weeks post-tDCS intervention
|
Changes in sleep onset latency, sleep efficiency, and nighttime sleep duration after tDCS intervention and 2 weeks post-tDCS intervention.
|
After tDCS intervention and 2 weeks post-tDCS intervention
|
|
Insomnia Severity Index score change
Time Frame: after tDCS intervention and 4 weeks post-intervention
|
the change in the Insomnia Severity Index (ISI) score after tDCS intervention and 4 weeks post-intervention.
|
after tDCS intervention and 4 weeks post-intervention
|
|
Hamilton Depression Rating Scale-17 change
Time Frame: After tDCS intervention, 2 weeks post-tDCS intervention, and 4 weeks post-intervention
|
Hamilton Depression Rating Scale 17 score change after tDCS intervention, 2 weeks post-tDCS intervention, and 4 weeks post-intervention.
For the HDRS17 , a score of 0-7 is generally accepted to be within the normal Hamilton Depression Rating Scale (HDRS) range (or in clinical remission), while a score of 20 or higher (indicating at least moderate severity) is usually required for entry into a clinical trial.
Higher scores indicate more severe depression.
|
After tDCS intervention, 2 weeks post-tDCS intervention, and 4 weeks post-intervention
|
|
Hamilton Anxiety Rating Scale Change
Time Frame: After tDCS intervention, 2 weeks post-tDCS intervention, and 4 weeks post-intervention
|
Hamilton Anxiety Rating Scale score change after tDCS intervention, 2 weeks post-tDCS intervention, and 4 weeks post-intervention.Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.
|
After tDCS intervention, 2 weeks post-tDCS intervention, and 4 weeks post-intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zhen Wang, PhD,MD, Shanghai Mental Health Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SMHC-ISM-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.